Election `97: Charity raised the cash for drug NHS could not afford
THE CANCER SUFFERER'S TALE
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Lynette Jackson had to resort to the collecting tin to pay for drug treatment for her cancer. The local health authority in Swindon where she lives said the drug, Taxol, which costs pounds 9,000 for a course of injections was too expensive for the NHS.
Her ovarian cancer was advanced and other treatments had failed to curb it. Aged 36 and denied the last chance the new drug offered, she turned to charity to provide the treatment the NHS could not. Her local paper the Swindon Evening Advertiser ran a campaign to raise the money and her treatment, paid for privately, was completed last month.
Mrs Jackson, who is married and has two children, saw her 47-year-old sister die from the disease last year. She said: "It is hard enough trying to fight the cancer without this extra pressure. I just want to highlight what a mess the system is in. All the doctors have been brilliant. They are just as angry as us about the whole thing."
Although Taxol, made from the Pacific Yew Tree, is not a cure, trials have shown it can extend life. The New England Journal of Medicine said in January last year that it should be regarded as "standard therapy for women with advanced ovarian cancer".
However, Wiltshire health authority claimed that the value of the drug was "not proven". It said that decisions about whether to provide expensive drugs such as Taxol were taken on the "best possible clinical evidence".
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments